Continuous intravenous infusions of famotidine maintain high intragastric pH in duodenal ulcer

H S MERKI, L WITZEL, D KAUFMAN, MARION KEMPF, J NEUMANN, J RÖHMEH, AND R P WALT

From the DRK Hospital, Mark Brandenburg, Department of Gastroenterology, Berlin, FRG, Department of Gastroenterology, Inselspital, Berne, Switzerland, Department of Statistics, Arzneimittelforschung, Berlin, FRG, and Department of Medicine, University of Birmingham, Birmingham

SUMMARY Three double blind crossover studies were carried out to assess the ability of primed infusions of famotidine to raise intragastric pH over 24 hours in 12 duodenal ulcer patients. pH was measured continuously using intragastric electrodes and solid state recording devices. The studies compared the effects of placebo, famotidine 10 mg bolus injection iv followed by continuous infusions of 3.2 mg/h and 4 mg/h in random order. Gastric acidity decreased significantly with both dose regimens (p<0.0005) but the effects of either dosage were similar. During fasting median pH rose from 1.35 to 7.1 and 7.05 respectively. During the day, when standard meals were taken, median pH rose from 1.30 to 4.3 and 3.65 respectively. Despite continuous infusions the H2-antagonist was less effective during this time. The latter finding raises questions about gastric secretory control during the day when food is eaten.

Intravenous antisecretory drugs are commonly used in patients with gastrointestinal bleeding,\(^1\,\,2\) in intensive care units\(^3\) and in anaesthesia.\(^4\,\,5\) The aim of such therapy is to raise the pH of the gastric milieu to a level at which peptic activity is minimal so that clot or mucosal digestion is limited. While it has been suggested that rebleeding from peptic lesions is decreased when pH rises to about pH 4,\(^7\) clear evidence that H2-receptor antagonists reduce rebleeding rates or mortality is lacking. A positive trend suggesting efficacy of cimetidine and ranitidine exists\(^8\) and a possible reason for such limited success is that existing dosage regimens produce less than optimum changes in gastric pH.\(^9\) It is clear that greater pharmacodynamic responses follow continuous infusions of H2-antagonists compared with bolus injections.\(^10\,\,14\) We have therefore measured the effect of continuous infusions of the new H2-receptor antagonist, famotidine (MSD, Yamanouchi), on gastric acidity measured continuously by intragastric glass electrodes.

Methods

Patients

Duodenal ulcer patients: 12 patients volunteered to undergo three separate studies. Written informed consent was obtained from each patient and the protocol was reviewed and accepted by the hospital ethical committee. The patients had all had at least one endoscopically proven episode of duodenal ulceration in the past year and healing had been confirmed. All were in symptomatic remission and nine had received no anti-ulcer therapy in the preceeding month. Three patients, however, completed courses of maintenance therapy (ranitidine 150 mg nocte) three days before the start of the first experiment and remained off treatment throughout. Concomitant drug use and previous gastric surgery were exclusion criteria.

Gastric Acidity

Measurements were recorded every five seconds from intragastric combined glass electrodes (Ingold AG) onto solid state devices (Ingold AG). Calibration was done before transnasal introduction of the electrode at pH 1.67, 4.01, and 7.00 and an automatic

Address for correspondence: Dr Hans S Merki, Inselspital Berne, CH-3010 Berne, Switzerland.

Received for publication 24 September 1987.
temperature correction was applied. Drift of the electrode was accepted if less than 0.15 unit and was checked after each recording period. Detailed methods and validation have previously been published.15–18

The patients attended the investigation ward in groups of 12 at 0600 h having fasted from midnight the night before. A cannula was placed into a forearm vein and the electrodes were passed into the stomach. In order to simulate conditions of hospitalisation the patients were confined to bed except for meals and bathing and cigarette smoking was not allowed. pH measurements started at 0800 h and continued until 0800 h the following day. Lunch was given at 1300 h, tea at 1600 h, supper at 1800 h and a snack at 2200 h (details are available on application to the authors). The menus for each study day were identical and extra food was not allowed.

**Drug Administration**

At 0800 a bolus injection was given over two minutes and a continuous infusion was started at a rate of 1 ml/h using mobile rechargeable pumps (Perfusor secura/Braun Mesulungen, FRG). The studies were randomised, crossover and double blind. The following regimens were compared: (a) Placebo 10 ml bolus followed by 1 ml/h (normal saline injection); (b) Famotidine 10 mg as a 10 ml bolus followed by 3.2 mg/h (80 mg in 25 ml normal saline); (c) Famotidine 10 mg as a 10 ml bolus followed by 4.0 mg/h (100 mg in 25 ml normal saline).

Routine haematological and biochemical screening and ECG were done before and after each study and 4 hourly blood pressure and pulse measurements were made during the studies.

**Data Processing and Statistical Analysis**

Data were transferred via floppy discs to a Harris computer and analysis was only done when all studies were complete. The following time periods were defined for analysis: 24 hours, fasted (0900–1300 h plus 2400–0800 h), and fed (1300–2400 h). Percentage of time with pH above 5.0 and 6.0 were defined as the primary and secondary variables of interest for statistical comparisons. Wilcoxon’s signed rank tests were used for the above comparisons between all study days. Probability values of p<0.05 were considered significant.

**Results**

The study was well tolerated and no side effects of drug administration were noted. Electrocardiographic abnormalities and significant changes in haematological and biochemical profiles were not seen. No studies were repeated through inadequate electrode function but one day’s data from one patient were lost because it was not able to be transferred from the recording device.

The mean age of the 12 patients (seven men, five women) was 45 (range 20–65) years (nine smokers, three non-smokers).

Figures 1a (placebo), b (famotidine 3.2 mg/h), and c (famotidine 4 mg/h) show all the individual 24 hour pH profiles and the median for each study day. Consistency of response was remarkable during the fasted period (only two profiles deviate far from the median during the night on active treatment), but responses were lower and less consistent during the fed period. The median pH profiles for all studies are shown in Figure 2. Median pH (interquartile range IQR) during the fasted period was 1.35 (1.1–2.0) on placebo, 7.1 (6.85–7.2) on famotidine 3.2 mg/h, and 7.05 (6.85–7.2) on famotidine 4 mg/h. During the fed period median pH (IQR) was 1.3 (1.15–1.7) on placebo, 4.3 (2.95–5.75) on famotidine 3.2 mg/h and was 3.65 (3.15–5.05) on famotidine 4 mg/h. Overall median 24 hour pH can be seen together with the above results in Figure 3. The Table shows the percentage of time pH was above the predefined levels of 5.0 and 6.0 during these time periods.

Significantly reduced acidity was found with both doses compared with placebo during all time periods (p<0.0001) but the small differences between the higher and lower famotidine doses were never statistically significant.

**Discussion**

The aim of this study was to investigate whether it was possible to raise intragastric pH to concentrations above 5.0 throughout a 24 hour period with continuous infusion of a potent H₂-receptor antagonist. We used higher doses than those recommended for standard duodenal ulcer therapy because we were aware of difficulties others had experienced in attempts to produce prolonged anacidity in patients with H₂-receptor antagonists.18–21 The doses used here are similar in terms of potency to those used previously when cimetidine 100 mg/h would not maintain pH above 4.0 in over 10% of acutely ill patients.

We wanted to raise pH consistently above 5 or even higher so as to limit peptic activity which may be important for prevention of stress ulceration,4,18–21 and prevent clot digestion which might be important in gastrointestinal bleeding.22

We have shown consistent responses of duodenal ulcer patients to continuous infusions of famotidine.

The change in pH we have measured is of similar order to that observed during intravenous omeprazole therapy.23 Primed infusions (10 mg followed by 3.2 mg/h) raised gastric pH well into the target range.
Continuous intravenous infusions of famotidine maintain high intragastric pH in duodenal ulcer

Fig. 1a 24 hour pH profiles of all patients during placebo. The individual profiles are all shown for 5 minute medians and the thick line represents the group medians. Meals are shown at the bottom by the arrows, L (lunch), T (tea), D (dinner), and S (snack). (b) 24 hour pH profiles of all patients during primed infusions of famotidine 3.2 mg/h. (c) 24 hour pH profiles of all patients during primed infusions of famotidine 4 mg/h.

Fig. 2 Median 24 hour pH profiles during placebo (dotted line), famotidine 3-2 mg/h (solid line) and famotidine 4 mg/h (broken line). Meals are shown as for Fig. 1.

when patients were not fed. Most patients on intensive care units and many patients with significant gastrointestinal haemorrhage are kept ‘nil by mouth’ and for these this dosage regimen should prove effective providing extrapolation from our controlled circumstances is valid. From our results, additional clinical benefit from higher dose infusions would not be expected.

Table Percentage of time above pH 5 and 6 during all treatments at all times

<table>
<thead>
<tr>
<th></th>
<th>Fasted pH&gt;5</th>
<th>Fasted pH&gt;6</th>
<th>Fed pH&gt;5</th>
<th>Fed pH&gt;6</th>
<th>24 hours pH&gt;5</th>
<th>24 hours pH&gt;6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pla</td>
<td>4-7</td>
<td>1-4</td>
<td>0-0</td>
<td>0-0</td>
<td>3-8</td>
<td>1-3</td>
</tr>
<tr>
<td>Fam 3-2 mg/h</td>
<td>86-5</td>
<td>84-7</td>
<td>42-0</td>
<td>7-5</td>
<td>69-1</td>
<td>49-6</td>
</tr>
<tr>
<td>Fam 4 mg/h</td>
<td>87-1</td>
<td>86-4</td>
<td>30-0</td>
<td>9-5</td>
<td>60-8</td>
<td>50-1</td>
</tr>
</tbody>
</table>
In these studies we chose to feed the patients standard meals. In some countries patients admitted
with gastrointestinal haemorrhage are not denied food and as far as possible we tried to simulate clinical
circumstances. It was also felt that bleeding itself may provide a stimulus to gastric secretion similar to that
of a high protein meal. We realised that eating may stimulate gastric acidity and affect the responses of
patients to a continuous infusion of an H₂-receptor antagonist and therefore predefined fasting and fed
periods for separate analysis. We were, however, surprised by the magnitude of the change which followed food. The return of acidity occurred in the patients despite continuous infusions of famotidine which had produced virtual anacidity before eating and is best seen in Figures 2 and 3. Active drug was continuing to be administered as is clear from the return of anacidity after midnight. The consistency of our results makes it almost impossible that the findings are spurious.

It is unclear why H₂-receptor antagonism seems less effective when patients are fed but similar
findings have previously been reported. Many speculations are possible: food may stimulate gastric
secretion through mechanisms (hormonal or neuro-
logical) which are unaffected by H₂-receptor antagonism.

It is well known, however, that H₂-blockade in man
does inhibit food, pentagastrin, and vagally induced
gastric secretion. The number of H₂-receptor sites
may increase in response to certain stimuli and the
‘new’ sites might not be adequately occupied by
circulating antagonists. Nevertheless the higher dose of famotidine was not more effective during the fed
period suggesting that higher concentrations of antagonist are not additionally useful. Others have
found that increasing the dose (and plasma concentra-
tion) of cimetidine does not enable one to
decrease acidity further in some patients. Famotidine, in common with ranitidine and cimetidine, is a competitive antagonist of H₂-
receptors and its antagonism is surmountable. It is
possible that after food, circulating H₂-agonist levels
rise high enough to replace the antagonist at the
receptor. In this case, however, one would expect
increasing doses of antagonist to be more effective
(although massive dosage increments may work but
formal investigations are required). It is also possible
that H₂-receptor blockade might increase the sensi-
tivity of the gastrin and cholinergic receptor. Further

**Fig. 3** Box-whisker plots of median pH values on all treatments during the 24 hours, fasted period (0900–1300 plus 2400–0800 h), and fed period (1300–2400 h). In these plots the median is shown as a solid horizontal line and the box around it represents the two quartiles. The mean is shown as a broken line. Whiskers above and below the box stretch to the furthest value within one interquartile distance from the quartiles. Values outside this range are shown separately as dots and arrows. (Full explanation in reference 17.)
Continuous intravenous infusions of famotidine maintain high intragastric pH in duodenal ulcer

Investigations are required to identify the mechanisms which limit the antisecretory effects of H2-receptor antagonists and which seem prominent during the day when people eat.

References

Continuous intravenous infusions of famotidine maintain high intragastric pH in duodenal ulcer.
H S Merki, L Witzel, D Kaufman, M Kempf, J Neumann, J Röhmel and R P Walt

*Gut* 1988 29: 453-457
doi: 10.1136/gut.29.4.453

Updated information and services can be found at:
http://gut.bmj.com/content/29/4/453

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections
Stomach and duodenum (1689)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/